Health Technology
Takeda Pharmaceutical Co., Ltd.
In the news
- Takeda offers early retirement to workers as young as 30 Aug 18, 2020
- AstraZeneca to supply Japan with 120m COVID-19 vaccine doses Aug 8, 2020
- Takeda starts trials of 3 COVID drugs in US with Amgen and AbbVie Aug 5, 2020
- Japan Inc says goodbye downtown, hello suburbs in post-pandemic era Jul 11, 2020
- Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2021 | JPY | USD |
| Revenue | 3,197.81B | 30,151.70M |
| Gross Profit | 1,798.37B | 16,956.61M |
| Operating income | 447,610M | 4,220.44M |
| Income before tax | 366,159M | 3,452.46M |
| Net income | 376,005M | 3,545.29M |
| EBITDA | 1,007.28B | 9,497.50M |
| Diluted EPS | 238.95 | 2.25 |
| Dividends Per Share | 180 | 1.69 |
| Total Assets | 12,912.29B | 116,853.33M |
| Total liabilities | 7,735.11B | 70,001.05M |
| Total equity | 5,168.89B | 46,777.35M |
| Operating cash flow | 905,073M | 8,533.80M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
| Revenue | 1,732.05B | 1,770.53B | 2,097.22B | 3,291.18B | 3,197.81B |
| Gross Profit | 1,017.65B | 1,148.86B | 1,275.55B | 1,789.37B | 1,798.37B |
| Operating income | 86,972M | 195,320M | 218,686M | 302,612M | 447,610M |
| Income before tax | 143,346M | 217,205M | 127,612M | -60,754M | 366,159M |
| Net income | 114,940M | 186,886M | 135,192M | 44,241M | 376,005M |
| EBITDA | 258,398M | 377,447M | 466,377M | 886,261M | 1,007.28B |
| Diluted EPS | 146.25 | 237.55 | 139.82 | 28.24 | 238.95 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 4,346.79B | 4,106.46B | 13,792.77B | 12,821.09B | 12,912.29B |
| Total liabilities | 2,397.82B | 2,089.05B | 8,606.78B | 8,093.60B | 7,735.11B |
| Total equity | 1,894.26B | 1,997.42B | 5,181.98B | 4,723.48B | 5,168.89B |
| Operating cash flow | 260,067M | 379,600M | 302,609M | 555,410M | 905,073M |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
| Revenue | 15,994.93M | 15,974.84M | 18,911.85M | 30,270.54M | 30,151.70M |
| Gross Profit | 9,397.74M | 10,365.80M | 11,502.42M | 16,457.72M | 16,956.61M |
| Operating income | 803.15M | 1,762.30M | 1,972.01M | 2,783.25M | 4,220.44M |
| Income before tax | 1,323.75M | 1,959.76M | 1,150.74M | -558.78M | 3,452.46M |
| Net income | 1,061.43M | 1,686.20M | 1,219.10M | 406.90M | 3,545.29M |
| EBITDA | 2,386.22M | 3,405.56M | 4,205.58M | 8,151.34M | 9,497.50M |
| Diluted EPS | 1.35 | 2.14 | 1.26 | 0.25 | 2.25 |
| Dividends Per Share | 1.66 | 1.62 | 1.62 | 1.65 | 1.69 |
| Total Assets | 39,009.18M | 38,612.71M | 124,612.85M | 118,763.31M | 116,853.33M |
| Total liabilities | 21,518.70M | 19,643.19M | 77,759.25M | 74,972.05M | 70,001.05M |
| Total equity | 16,999.56M | 18,781.60M | 46,817.41M | 43,754.18M | 46,777.35M |
| Operating cash flow | 2,401.63M | 3,424.99M | 2,728.79M | 5,108.35M | 8,533.80M |
Valuation Measures
| Mar 2021 | |
| PER | 16.55 |
| ROA | 2.92% |
| ROE | 7.60% |
| Operating margin | 13.99% |
| Profit margin | 11.75% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer & Director: Constantine Saroukos
- Director, Research & Development President: Andrew S. Plump
- Chief Medical & Scientific Officer: Michael E. Mendelsohn
- Chief Ethics & Compliance Officer: Mwana Lugogo
Shareholders
- Nomura Asset Management Co., Ltd. (4.1%)
- BlackRock Fund Advisors (3.2%)
- The Vanguard Group, Inc. (2.2%)
- Nippon Life Insurance Co. (2.2%)
- Daiwa Asset Management Co. Ltd. (1.9%)
- Nikko Asset Management Co., Ltd. (1.9%)
- Norges Bank Investment Management (1.5%)
- BlackRock Japan Co., Ltd. (1.4%)
- Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.9%)
- Baillie Gifford & Co. (0.8%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Takeda Pharmaceutical Co. Ltd. /Prescription Pharma Ass
- Takeda Dunboyne Biologics Ltd.
- Plasmaspendedienst GmbH
- Gaido Health, Inc.
- Takeda Belgium
- Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
- Takeda Re Insurance AG
- Plasmapunkt Favoriten GmbH
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Pvp Biologics, Inc.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
- Takeda Mexico SA de CV
- Takeda Kazakhstan LLP
- Takeda Pharmaceuticals Korea Co., Ltd.
Competitors
- AstraZeneca PLC
- Green Cross Corporation
- Grifols, S.A. Class A
- Amgen Inc.
- Roche Holding Ltd
- Karyopharm Therapeutics, Inc.
- Amicus Therapeutics, Inc.
- Protalix Biotherapeutics, Inc.
- ADMA Biologics, Inc.
- Novartis AG
- Sanofi
- Pfizer Inc.
- Merck & Co., Inc.
- Johnson & Johnson
- AbbVie, Inc.
- Bristol-Myers Squibb Company
- CSL Limited
- Bayer AG
- UCB S.A.
- Merck KGaA
- Swedish Orphan Biovitrum AB
- Novo Nordisk A/S Class B
- JCR Pharmaceuticals Co., Ltd.
- Pharming Group NV
- Oncopeptides AB
- ISU Abxis Co., Ltd.
- BioCryst Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Kendrion N.V.
- Ipsen SA
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 26 Jul, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.